Navigation Links
Mumps vaccine coverage should be improved, study finds
Date:8/24/2010

Although immunity to mumps is high in the United States, mumps vaccine coverage must be maintained and improved to prevent future outbreaks, according to a new study, now available online (http://www.journals.uchicago.edu/doi/full/10.1086/655394), in the September 1, 2010 issue of The Journal of Infectious Diseases.

Mumpsa viral illness found in most parts of the worldcan cause serious complications, including deafness, sterility, meningitis, and encephalitis. Since 1977, mumps vaccination has been recommended in the U.S. and is given as part of the MMR (measles-mumps-rubella) vaccine. Two doses are currently recommended for children. By 2000, the annual number of reported U.S. mumps cases had declined to less than 500. But in 2006, the country's largest mumps outbreak in 20 years began on college campuses in Iowa and resulted in more than 6,000 reported cases. This event raised questions about how to prevent future outbreaks and about the feasibility of eliminating mumps.

To measure the U.S. population's immunity to mumps, Preeta K. Kutty, MD, MPH, and other researchers at the Centers for Disease Control and Prevention (CDC) obtained blood samples from 6- to 49-year-old participants in a nationwide health survey and tested the samples for antibodies to mumps. Serum samples were tested and survey data were collected during 1999� from more than 15,000 people. Researchers found that 90 percent of the participants had antibodies to mumps; this is on the lower end of what is needed to protect the overall population through "herd immunity"the proportion of the population that needs to be vaccinated to stop transmission of mumps.

Among study participants old enough to have had mumps as children (those born between 1949 and 1966), 92 to 93 percent had mumps antibodies. Among those likely to have been vaccinated (those born after 1976), 90 percent had mumps antibodies. For those born during 1967 to 1976, the percentage of those with antibodies was even lower: 85 to 86 percent. There were also differences in relation to race, ethnic origin, birthplace, and sex.

Although the percentage of persons with mumps antibodies was on the lower end of what is considered necessary for herd immunity, the study authors note that the incidence of mumps has declined by 96 percent or more since the pre-vaccine era. However, to maintain this success against this serious viral infection, the study authors believe it is crucial to maintain or, preferably, improve vaccine coverage to prevent or control future outbreaks.

The findings emphasize the "importance of achieving and maintaining a high rate of vaccination in the community, continuing surveillance for mumps, promptly reporting known and suspected cases of mumps to public health officials so that they can take immediate steps to stop further spread of the virus, and studying and understanding the changing factors that affect the introduction and spread of mumps in the U.S.," Dr. Kutty said.

In an accompanying editorial, Patricia Quinlisk, MD, MPH, state epidemiologist and medical director with the Iowa Department of Public Health, agreed with the study authors, noting that over time, immunity to mumps may diminish. This can occur even after a second dose of the MMR vaccine, which was recommended, starting in 1989, for children entering school. To ensure individual lifelong immunity and appropriate levels of herd immunity, Quinlisk suggested that a third dose may be needed or that the second dose should be delayed until later in adolescence. The study's findings "will help us to understand and use the public health strategies that will best control mumps today," Dr. Quinlisk wrote.


'/>"/>

Contact: John Heys
jheys@idsociety.org
703-299-0412
Infectious Diseases Society of America
Source:Eurekalert

Related medicine news :

1. Unvaccinated Boys at Risk of Mumps-Linked Testicular Problem
2. Vaccine Not Fail-Safe in Ongoing Mumps Outbreak
3. Survey of American women finds STD vaccine viewed positively
4. More U.S. Teens Get Recommended Vaccines
5. New human adenovirus may not make for good vaccines, after all
6. Human clinical trial of NIH-developed dengue vaccine begins
7. UR discovers new way to boost vaccines, seeks patent
8. Alphavirus-based vaccine may slow some cancers
9. Boosting the efficacy of anticancer vaccines
10. Vaccine Shows Some Promise Against Advanced Cancers
11. H1N1 Protection in Coming Seasons Flu Vaccines: FDA
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/29/2016)... ... April 29, 2016 , ... On Tuesday, April 26, ... the Southeast, celebrated the signature of Gov. Nathan Deal on SB 258, the “Rural ... (R - Cumming), offers a 70% tax credit to individuals and corporations which donate ...
(Date:4/29/2016)... Fort Stewart, GA (PRWEB) , ... April 29, 2016 , ... ... on Monday, May 16, 2016, at its new location in the Exchange Furniture Mall ... including a raffle for a 50-inch Samsung Smart TV. Plus attendees will have the ...
(Date:4/29/2016)... ... April 29, 2016 , ... ... announces the Gyrociser, an exercise invention which aids in proper muscle development. , ... Cooper, CEO and Creative Director of World Patent Marketing. "Globalization has threatened the ...
(Date:4/29/2016)... ... April 29, 2016 , ... Reltok Nasal Products proudly announces that Boston Medical ... neck/ear, nose and throat specialty, has added the KOTLER NASAL AIRWAY™ to its diverse ... is a newly patented safety device secured by nasal surgeons onto the floor of ...
(Date:4/29/2016)... , ... April 29, 2016 , ... ... print media enterprise focused entirely on patients with cancer, today announced that Lynne ... chosen as the 2016 CURE® Extraordinary Healer® for Oncology Nursing , which ...
Breaking Medicine News(10 mins):
(Date:4/29/2016)... 29, 2016 ReportsnReports.com adds ... market research report that provides an overview of ... at various stages, therapeutics assessment by drug target, ... and molecule type, along with latest updates, and ... key players involved in the therapeutic development for ...
(Date:4/29/2016)... , April 29, 2016 ... glyco-biology expertise, today announces the appointment of Dr. ... Dr. Zurlo is an oncologist with many years clinical ... and biotechnology industries. His last role was at Mologen ... of the Executive Board. Previously Dr. Zurlo held various ...
(Date:4/28/2016)... 28, 2016  While Abbott,s announced purchase of ... valve repair and stent business, healthcare research firm ... more firmly into patient monitoring.  Kalorama said that ... device areas, with double-digit growth expected the next ... Advanced Remote Patient Monitoring . Abbott Laboratories ...
Breaking Medicine Technology: